Tuesday's ETF with Unusual Volume: RSHO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: NASDAQ.COM
High Trading Volume: The Tema American Reshoring ETF experienced significant trading activity on Tuesday, with over 2.1 million shares traded compared to an average of about 69,000 shares, and the ETF's shares rose by approximately 2.8%.
Top Performers: Key components of the ETF included Taiwan Semiconductor Manufacturing and CRH, both showing gains, while SPX Technologies had the highest increase at 4.6%, and Emerson Electric lagged behind with a modest rise of 0.5%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRH
Wall Street analysts forecast CRH stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 111.240
Low
133.56
Averages
146.03
High
164.70
Current: 111.240
Low
133.56
Averages
146.03
High
164.70
About CRH
CRH PLC is an Ireland-based company. The Company manufactures and distributes a diverse range of superior building materials and products, which are used in construction projects of all sizes. It operates in three segments across two divisions. Its divisions include Americas and International. Its Americas Division comprises two segments: Americas Materials Solutions and Americas Building Solutions. Americas Materials Solutions provides building materials for the construction and maintenance of public infrastructure and commercial and residential buildings in North America. The primary materials produced by this segment include aggregates, cement, readymixed concrete and asphalt. Americas Building Solutions manufactures, supplies and delivers solutions for the built environment in communities across North America. Its International Division, which comprises one segment, International Solutions, is a provider of integrated building solutions primarily across Europe and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Dynamics and Corporate Mergers Overview
- Muted Market Start: The new trading week begins with the S&P 500 indicated flat while the tech-heavy Nasdaq shows slight gains, and WTI crude oil is trading around $76.50 per barrel, reflecting cautious market sentiment regarding economic outlook.
- Abbvie Acquires Apogee: Abbvie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio, particularly competing with Johnson & Johnson's Tremfya through its top drug Skyrizi, which is expected to enhance Abbvie's competitive edge in the biopharmaceutical market.
- CRH Acquires Arcosa: CRH is acquiring Arcosa for $8.5 billion, stating that the acquisition is highly complementary amid growing demand for energy and utility infrastructure, which is expected to further solidify CRH's position in the construction materials market.
- Estee Lauder Buy Rating Reinstated: Goldman Sachs has reinstated a buy rating for Estee Lauder with a price target of $100, as analysts believe the market is underestimating the company's growth momentum, especially after it walked away from merger talks with Spanish beauty peer Puig.
See More
CRH to Acquire Arcosa for $8.5 Billion, Enhancing Market Position
- Acquisition Details: CRH plc announced its agreement to acquire Arcosa, Inc. for $150 per share in cash, valuing the deal at approximately $8.5 billion, which represents a 25% premium over Arcosa's 60-day trading VWAP, thereby reinforcing CRH's leadership in the U.S. aggregates market.
- Complementary Business: The acquisition is viewed as highly complementary to CRH's connected portfolio strategy, with Arcosa's Construction Products business operating 109 quarries and approximately 35 million tons of aggregate shipments expected in 2025, which will enhance CRH's competitive edge.
- Cost Synergies: CRH anticipates achieving $175 million in run-rate cost synergies by the third year post-transaction, primarily through operational improvements, procurement efficiencies, and integration benefits, significantly boosting the company's profitability and cash flow.
- Transaction Timeline: The acquisition is expected to close in the first quarter of 2027, with CRH shares trading up 0.03% and Arcosa shares up 7.27% in pre-market activity, indicating a positive market reaction to the deal.
See More
AbbVie Acquires Apogee, Shares Surge 50%
- AbbVie Acquires Apogee: Apogee Therapeutics' shares soared 50% after AbbVie confirmed its acquisition for $10.9 billion, valuing shares at $135.11 each, a 49% premium over Thursday's close, which will enhance AbbVie's presence in the respiratory market.
- CRH Acquires Arcosa: Shares of Arcosa rose over 7% following CRH's announcement of an $8.5 billion acquisition, with a cash offer of $150 per share, representing a 10% premium from Thursday's close, strategically enhancing CRH's product portfolio.
- Getty Images Surge: Getty Images' stock surged 150% after announcing a partnership with OpenAI, although its market cap remains below $1 billion, indicating strong market expectations for future growth potential.
- Micron Technology Gains: Micron Technology's stock increased by 4.5% after Bernstein and Needham raised their price targets to $1,300 and $1,550 respectively, reflecting optimistic market sentiment regarding its future performance.
See More
CRH to Acquire Arcosa for $8.5 Billion
- Acquisition Scale: CRH announced its acquisition of infrastructure-related products provider Arcosa for approximately $8.5 billion, offering $150 per share, which represents a 10.4% premium over Arcosa's last closing price, indicating CRH's recognition of its market value.
- Positive Market Reaction: Following the acquisition announcement, Arcosa's shares rose 7.4% in premarket trading to $146, reflecting investor optimism about the deal and potentially boosting Arcosa's market confidence.
- Transaction Timeline: The acquisition is expected to close in the first quarter of 2027, allowing CRH to further expand its market share in the infrastructure sector and enhance its competitive position.
- Financial Advisory Teams: J.P. Morgan and Morgan Stanley are acting as financial advisors to CRH, while Evercore and Goldman Sachs are advising Arcosa, showcasing the professional support both parties have in transaction structuring and financing.
See More
CRH Acquires Arcosa to Strengthen Market Leadership in Infrastructure
- Acquisition Overview: CRH has announced an all-cash acquisition of Arcosa for $150 per share, valuing the transaction at approximately $8.5 billion with a 25% premium, expected to close in Q1 2027, further solidifying CRH's leadership in the North American infrastructure market.
- Strategic Synergies: The acquisition will add 35 million tons of high-quality natural and recycled aggregates annually to CRH's portfolio, enhancing its position in the U.S. with over 265 million tons of annual production and expanding its market share in rapidly growing metropolitan statistical areas.
- Expected Financial Benefits: The transaction is anticipated to positively impact CRH's earnings, margins, and cash flow within the first 12 months post-completion, with projected cost synergies of $175 million by year three, demonstrating CRH's ongoing commitment to value-creating capital allocation.
- Market Outlook: CRH's CEO stated that this acquisition places the company at the forefront of immense growth opportunities as demand for energy and utility infrastructure solutions accelerates, further driving the achievement of its 2030 financial targets.
See More
CRH to Acquire 100% of Arcosa in $8.5B Cash Deal
- Acquisition Overview: CRH has signed an agreement to acquire 100% of Arcosa for $150 per share in an all-cash transaction valued at approximately $8.5 billion, expected to close in Q1 2027 pending stockholder and regulatory approvals.
- Financial Metrics: The transaction values Arcosa at an acquisition multiple of 11.5x 2026E adjusted EBITDA, with anticipated annual run-rate cost synergies of $175 million by year three, highlighting the financial attractiveness of the deal.
- Market Reaction: Following the announcement, Arcosa shares rose nearly 12% in premarket trading, reflecting positive market sentiment and investor confidence in the acquisition.
- Strategic Implications: This acquisition is highly complementary to CRH's connected portfolio strategy and is expected to be accretive to earnings, margin, and cash flow within the first 12 months post-completion, further solidifying CRH's market position in infrastructure materials.
See More
Market Dynamics and Corporate Mergers Overview
- Muted Market Start: The new trading week begins with the S&P 500 indicated flat while the tech-heavy Nasdaq shows slight gains, and WTI crude oil is trading around $76.50 per barrel, reflecting cautious market sentiment regarding economic outlook.
- Abbvie Acquires Apogee: Abbvie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio, particularly competing with Johnson & Johnson's Tremfya through its top drug Skyrizi, which is expected to enhance Abbvie's competitive edge in the biopharmaceutical market.
- CRH Acquires Arcosa: CRH is acquiring Arcosa for $8.5 billion, stating that the acquisition is highly complementary amid growing demand for energy and utility infrastructure, which is expected to further solidify CRH's position in the construction materials market.
- Estee Lauder Buy Rating Reinstated: Goldman Sachs has reinstated a buy rating for Estee Lauder with a price target of $100, as analysts believe the market is underestimating the company's growth momentum, especially after it walked away from merger talks with Spanish beauty peer Puig.
See More
CRH to Acquire Arcosa for $8.5 Billion, Enhancing Market Position
- Acquisition Details: CRH plc announced its agreement to acquire Arcosa, Inc. for $150 per share in cash, valuing the deal at approximately $8.5 billion, which represents a 25% premium over Arcosa's 60-day trading VWAP, thereby reinforcing CRH's leadership in the U.S. aggregates market.
- Complementary Business: The acquisition is viewed as highly complementary to CRH's connected portfolio strategy, with Arcosa's Construction Products business operating 109 quarries and approximately 35 million tons of aggregate shipments expected in 2025, which will enhance CRH's competitive edge.
- Cost Synergies: CRH anticipates achieving $175 million in run-rate cost synergies by the third year post-transaction, primarily through operational improvements, procurement efficiencies, and integration benefits, significantly boosting the company's profitability and cash flow.
- Transaction Timeline: The acquisition is expected to close in the first quarter of 2027, with CRH shares trading up 0.03% and Arcosa shares up 7.27% in pre-market activity, indicating a positive market reaction to the deal.
See More
AbbVie Acquires Apogee, Shares Surge 50%
- AbbVie Acquires Apogee: Apogee Therapeutics' shares soared 50% after AbbVie confirmed its acquisition for $10.9 billion, valuing shares at $135.11 each, a 49% premium over Thursday's close, which will enhance AbbVie's presence in the respiratory market.
- CRH Acquires Arcosa: Shares of Arcosa rose over 7% following CRH's announcement of an $8.5 billion acquisition, with a cash offer of $150 per share, representing a 10% premium from Thursday's close, strategically enhancing CRH's product portfolio.
- Getty Images Surge: Getty Images' stock surged 150% after announcing a partnership with OpenAI, although its market cap remains below $1 billion, indicating strong market expectations for future growth potential.
- Micron Technology Gains: Micron Technology's stock increased by 4.5% after Bernstein and Needham raised their price targets to $1,300 and $1,550 respectively, reflecting optimistic market sentiment regarding its future performance.
See More
CRH to Acquire Arcosa for $8.5 Billion
- Acquisition Scale: CRH announced its acquisition of infrastructure-related products provider Arcosa for approximately $8.5 billion, offering $150 per share, which represents a 10.4% premium over Arcosa's last closing price, indicating CRH's recognition of its market value.
- Positive Market Reaction: Following the acquisition announcement, Arcosa's shares rose 7.4% in premarket trading to $146, reflecting investor optimism about the deal and potentially boosting Arcosa's market confidence.
- Transaction Timeline: The acquisition is expected to close in the first quarter of 2027, allowing CRH to further expand its market share in the infrastructure sector and enhance its competitive position.
- Financial Advisory Teams: J.P. Morgan and Morgan Stanley are acting as financial advisors to CRH, while Evercore and Goldman Sachs are advising Arcosa, showcasing the professional support both parties have in transaction structuring and financing.
See More
CRH Acquires Arcosa to Strengthen Market Leadership in Infrastructure
- Acquisition Overview: CRH has announced an all-cash acquisition of Arcosa for $150 per share, valuing the transaction at approximately $8.5 billion with a 25% premium, expected to close in Q1 2027, further solidifying CRH's leadership in the North American infrastructure market.
- Strategic Synergies: The acquisition will add 35 million tons of high-quality natural and recycled aggregates annually to CRH's portfolio, enhancing its position in the U.S. with over 265 million tons of annual production and expanding its market share in rapidly growing metropolitan statistical areas.
- Expected Financial Benefits: The transaction is anticipated to positively impact CRH's earnings, margins, and cash flow within the first 12 months post-completion, with projected cost synergies of $175 million by year three, demonstrating CRH's ongoing commitment to value-creating capital allocation.
- Market Outlook: CRH's CEO stated that this acquisition places the company at the forefront of immense growth opportunities as demand for energy and utility infrastructure solutions accelerates, further driving the achievement of its 2030 financial targets.
See More
CRH to Acquire 100% of Arcosa in $8.5B Cash Deal
- Acquisition Overview: CRH has signed an agreement to acquire 100% of Arcosa for $150 per share in an all-cash transaction valued at approximately $8.5 billion, expected to close in Q1 2027 pending stockholder and regulatory approvals.
- Financial Metrics: The transaction values Arcosa at an acquisition multiple of 11.5x 2026E adjusted EBITDA, with anticipated annual run-rate cost synergies of $175 million by year three, highlighting the financial attractiveness of the deal.
- Market Reaction: Following the announcement, Arcosa shares rose nearly 12% in premarket trading, reflecting positive market sentiment and investor confidence in the acquisition.
- Strategic Implications: This acquisition is highly complementary to CRH's connected portfolio strategy and is expected to be accretive to earnings, margin, and cash flow within the first 12 months post-completion, further solidifying CRH's market position in infrastructure materials.
See More
